Intravenous antiepileptic drugs in adults with benzodiazepine-resistant convulsive status epilepticus: A systematic review and network meta-analysis.

Brigo, Francesco; Del Giovane, Cinzia; Nardone, Raffaele; Trinka, Eugen; Lattanzi, Simona (2019). Intravenous antiepileptic drugs in adults with benzodiazepine-resistant convulsive status epilepticus: A systematic review and network meta-analysis. Epilepsy & behavior, 101(Pt B), p. 106466. Elsevier 10.1016/j.yebeh.2019.106466

[img] Text
Brigo EpilepsyBehav 2019_epub.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (994kB) | Request a copy
[img] Text
Brigo EpilepsyBehav 2019_postprint.pdf - Accepted Version
Restricted to registered users only until 26 August 2020.
Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND).

Download (546kB) | Request a copy

AIM The aim of this study was to estimate the comparative efficacy and safety of antiepileptic drugs (AEDs) in adults with benzodiazepine-resistant convulsive status epilepticus (SE). METHODS MEDLINE, CENTRAL, ClinicalTrials.gov, and Opengrey.eu were searched (from inception to 3rd April, 2018) for randomized controlled trials (RCTs) of AEDs used intravenously to treat benzodiazepine-resistant SE in adults. Efficacy outcomes were SE cessation within 1 h from drug administration and seizure freedom at 24 h. Safety outcomes were respiratory depression and hypotension. Effect sizes were estimated by network meta-analyses within a frequentist framework. The hierarchy of competing interventions was established using the surface under the cumulative ranking curve (SUCRA) and mean ranks. RESULTS Five RCTs were considered, involving 349 patients. Included interventions were valproate (VPA; 20-30 mg/kg), phenytoin (PHT; 20 mg/kg), diazepam (DZP; 0.2 mg/kg, then 4 mg/h), phenobarbital (PHB; 20 mg/kg, then 100 mg every 6 h), lacosamide (LCM; 400 mg), and levetiracetam (LEV; 20 mg/kg); PHB was superior to PHT, VPA, DZP, LEV, and LCM with respect to SE cessation and performed better than VPA, DZP, and LCM in the achievement of seizure freedom at 24 h. No differences were noted between drugs in the occurrence of respiratory depression and hypotension. According to SUCRA, PHB had the greatest probabilities of being best in the achievement of SE control and seizure freedom, whereas VPA and LCM ranked best for the safety outcomes. CONCLUSIONS Our study suggests that high-dose PHB is effective in controlling SE and preventing seizure recurrence, and LCM and VPA could be better tolerated options. Further head-to-head comparative studies are strongly required to provide more definitive evidence. This article is part of the Special Issue "Proceedings of the 7th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures".

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Medical Education > Institute of General Practice and Primary Care (BIHAM)

UniBE Contributor:

Del Giovane, Cinzia

Subjects:

600 Technology > 610 Medicine & health
300 Social sciences, sociology & anthropology > 360 Social problems & social services

ISSN:

1525-5050

Publisher:

Elsevier

Language:

English

Submitter:

Doris Kopp Heim

Date Deposited:

19 Sep 2019 11:04

Last Modified:

08 Jan 2020 01:31

Publisher DOI:

10.1016/j.yebeh.2019.106466

PubMed ID:

31462385

Uncontrolled Keywords:

Efficacy Network meta-analysis Safety Status epilepticus

BORIS DOI:

10.7892/boris.133363

URI:

https://boris.unibe.ch/id/eprint/133363

Actions (login required)

Edit item Edit item
Provide Feedback